AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously ...

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a ...

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline ...